Impact of a modified screening approach during the COVID-19 pandemic on the diagnosis and outcomes of gestational diabetes mellitus: A population-level analysis of 90,518 pregnant women
- PMID: 37857500
- DOI: 10.1111/dme.15247
Impact of a modified screening approach during the COVID-19 pandemic on the diagnosis and outcomes of gestational diabetes mellitus: A population-level analysis of 90,518 pregnant women
Abstract
Aims: To provide real-world evidence on the uptake of and outcomes associated with the modified gestational diabetes mellitus (GDM) screening approach offered during the COVID-19 pandemic compared with the standard screening approach.
Methods: All pregnancies between 01 January 2020 and 31 December 2021, in Alberta, Canada, were included in the study. We examined GDM screening and diagnosis rates, and large-for-gestational-age (LGA) outcomes.
Results: Annual GDM screening rates were > 95% during the study time period. Overall, 84.7%, and 11.6% of the 92,505 pregnancies underwent standard and modified screening for GDM, respectively. The use of modified screening was the highest among deliveries in August 2020 (49.8%) which corresponded to the early first wave of the pandemic. GDM diagnosis rate was lower in the modified screening (7.4%) than in the standard screening (12.3%, p < 0.001) group. The LGA rates in the modified screening with GDM and the standard screening with GDM groups were 24.8% and 12.6%, respectively (p < 0.001). Women in the modified screening with GDM group were at a higher risk of having an LGA infant (adjusted odds ratio: 3.46; 95% confidence interval: 2.93, 4.08) compared to the standard screening with no GDM group.
Conclusions: The COVID-19 epidemic had no impact on screening for GDM. Women who underwent modified screening, based on HbA1c/random plasma glucose, had lower rates of GDM cases.
Keywords: COVID-19 pandemic; diagnosis; gestational diabetes mellitus; large-for-gestational-age; screening.
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
References
REFERENCES
-
- Yamamoto JM, Donovan LE, Feig DS, Berger H. Urgent Update - Temporary Alternative Screening Strategy for Gestational Diabetes Screening During the COVID-19 Pandemic - The Joint Consensus Statement from the Diabetes Canada Clinical Practice Guidelines Steering Committee and the Society of Obstetricians and Gynecologists of Canada. 2020:1-5. https://els-jbs-prod-cdn.jbs.elsevierhealth.com/pb/assets/raw/health%20a...
-
- Yamamoto JM, Donovan LE, Feig DS, Berger H. Temporary alternative screening strategy for gestational diabetes screening during the COVID-19 pandemic-the need for a middle ground. Can J Diabetes. 2022;46(2):204-206. doi:10.1016/j.jcjd.2021.08.008
-
- Vambergue A, Jacqueminet S, Lamotte MF, et al. Three alternative ways to screen for Hyperglycaemia in pregnancy during the COVID-19 pandemic. Diabetes Metab. 2020;46(6):507-510. doi:10.1016/j.diabet.2020.04.003
-
- Torlone E, Festa C, Formoso G, et al. Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: position statement of the Italian Association of Clinical Diabetologists (AMD) and the Italian diabetes society (SID), diabetes, and pregnancy study group. Nutr Metab Cardiovasc Dis. 2020;30(9):1418-1422. doi:10.1016/j.numecd.2020.05.023
-
- Kasuga Y, Saisho Y, Ikenoue S, Ochiai D, Tanaka M. A new diagnostic strategy for gestational diabetes during the COVID-19 pandemic for the Japanese population. Diabetes Metab Res Rev. 2020;36(8):e3351. doi:10.1002/dmrr.3351
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
